BRIEF: Galapagos and Gilead add Lupus to their Growing List of Indications

Galapagos has announced a new Phase II study led by its partner Gilead to evaluate filgotinib in women suffering from cutaneous lupus erythematosus. 

Filgotinib is under evaluation for yet another indication, cutaneous lupus erythematosus, in a new Phase II trial. The antibody is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis, and the team recently announced three new Phase II trials in Sjögren’s syndrome, ankylosing spondylitis, and psoriatic arthritis.

Filgotinib’s wide range of applications boils down to its ability to block JAK1, a protein involved in multiple inflammatory signaling pathways. Other biotechs targeting lupus include TxCell, which is developing a CAR-Treg cell therapy, and NeoVacs, which is working on a vaccine that targets interferon alpha (IFNα).


Cover image from Andres Court /Shutterstock

Previous post

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Next post

Unstable Chromosomes can Predict Lung Cancer Comebacks Much Faster

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.